Novozymes reported estimate-beating Q3 23 numbers, underpinned by continuing momentum in BioEnergy as well as a strong recovery in the key consumer-facing businesses. The weakness in the textile and grain processing segments and still persistent destocking headwinds across multiple business areas remain the swing factors with respect to the FY23 outlook. We do not expect significant revisions to our estimates.